BioClinica to Highlight New Trident IWR Release at DIA
BioClinica, Inc.announced a new release of Trident IWR, the latest addition to its best-in-class suite of eClinical applications. BioClinica will highlight Trident and other new product offerings at booth #1417, providing demonstrations of BioClinica’s Integrated Clinical Trial Solutions, including:
- Trident IWR Randomization to Express EDC
- Express CRF Status to OnPoint CTMS and Clinical Payment Manager
- Trident + Optimizer 360 Degree Clinical Supplies Forecasting and Management
- Unified Reporting
- Customer Portals
- Microsoft Office Interoperability
- Ad Hoc Reporting
BioClinica will also participate in a clinical solutions showcase for the Microsoft platform, where they will demonstrate BioClinica’s open, standards-based architecture within the Microsoft Connected Life Sciences Framework guidance.
To see the benefits of this solution, please visit Microsoft at booth #1111 and BioClinica at booth #1417.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
